🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in South Korea / NCT06537752
Recruiting Observational

A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer Patients

NCT06537752 · tracked via the Priya Life Science South Korea tracker
Phase
Observational
Started
2024-07-15
Last updated
2025-09-12

Condition(s) studied

Breast Cancer

Study summary

The purpose of this study is to evaluate ethanol-induced symptoms and safety in breast cancer patients with neoadjuvant/adjuvant chemotherapy including Non-ethanol formulation docetaxel before and after surgery

Eligibility

Sex
FEMALE
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Those who voluntarily signed a written personal information collection and usage agreement after receiving an explanation about the objective and method, etc. of this clinical study. * Those are confirmed to have primary breast cancers through histological diagnosis and one of the following are applicable. * Those who need neoadjuvant chemotherapy as breast cancer patients * Those who need adjuvant chemotherapy after breast cancer surgery * Those who are scheduled to administer non-ethanol formulation docetaxel according to chemotherapy * Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion. Exclusion Criteria: * Those are diagnosed with other primary cancer that can influence the treatment or prognosis of primary breast cancers. * Those are diagnosed with secondary breast cancers. * Those with Stage 0/1 (Tis, N0, M0) or Stage IV (any T, Any N, M1) breast cancers.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Chung-Ang University Hospital Seoul South Korea Recruiting
Uijeongbu Eulji Medical Center, Eulji University Uijeongbu-si South Korea Not Yet Recruiting

More Boryung Pharmaceutical Co., Ltd trials in South Korea

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06537752 on ClinicalTrials.gov ↗ ← All trials in South Korea